4,376 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Citizens Financial Group Inc. RI

Key Points

• Citizens Financial Group purchased 4,376 Regeneron shares worth approximately $2.73 million, while institutional investors collectively own 83.31% of the company.
• Regeneron reported quarterly EPS of $14.29, exceeding the $10.16 consensus estimate, with revenue up 16.7% year over year to $4.29 billion.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $801.70; the stock recently opened at $805.93 and carries a quarterly dividend of $0.94 per share.

Citizens Financial Group Inc. RI purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 4,376 shares of the biopharmaceutical company's stock, valued at approximately $2,729,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. WPG Advisers LLC grew its stake in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 25 shares during the last quarter. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $26,000. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $29,000. Finally, Trust Co. of Vermont acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $29,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on REGN shares. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. Leerink Partners upped their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a research report on Monday. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a "buy" rating in a research note on Thursday, April 23rd. HSBC lowered their target price on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating on the stock in a report on Monday, July 6th. Finally, Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a "hold" rating in a research note on Wednesday, July 29th. Sixteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $801.70.

Regeneron Pharmaceuticals Stock Up 0.3%

Regeneron Pharmaceuticals stock opened at $805.93 on Tuesday. The stock's 50 day moving average price is $679.69 and its 200 day moving average price is $714.24. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11. The company has a market cap of $82.98 billion, a PE ratio of 19.92, a price-to-earnings-growth ratio of 1.37 and a beta of 0.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same quarter in the prior year, the business posted $12.81 earnings per share. Regeneron Pharmaceuticals's revenue was up 16.7% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Insider Activity

In other news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the sale, the director owned 603 shares of the company's stock, valued at $482,400. This trade represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock worth $1,090,030 in the last 90 days. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source